B. Metzler seel. Sohn & Co. AG Sells 13,400 Shares of Inspire Medical Systems, Inc. $INSP

B. Metzler seel. Sohn & Co. AG trimmed its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 52.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,362 shares of the company’s stock after selling 13,400 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Inspire Medical Systems were worth $917,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dragoneer Investment Group LLC boosted its holdings in Inspire Medical Systems by 81.4% during the 2nd quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock valued at $305,532,000 after acquiring an additional 1,056,808 shares during the period. Wasatch Advisors LP grew its holdings in shares of Inspire Medical Systems by 7.2% in the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after purchasing an additional 110,288 shares during the last quarter. William Blair Investment Management LLC increased its stake in Inspire Medical Systems by 68.7% in the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after buying an additional 528,404 shares during the period. State Street Corp increased its stake in Inspire Medical Systems by 2.3% in the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after buying an additional 22,843 shares during the period. Finally, Frontier Capital Management Co. LLC lifted its holdings in Inspire Medical Systems by 59.9% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 693,203 shares of the company’s stock valued at $89,957,000 after buying an additional 259,716 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on INSP shares. Mizuho dropped their target price on shares of Inspire Medical Systems from $130.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, February 12th. UBS Group set a $67.00 price target on shares of Inspire Medical Systems in a research note on Friday, February 13th. Evercore reissued an “outperform” rating on shares of Inspire Medical Systems in a research note on Friday, February 27th. Morgan Stanley set a $60.00 price objective on Inspire Medical Systems in a report on Wednesday, February 18th. Finally, Truist Financial decreased their target price on Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, February 12th. Five equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Inspire Medical Systems has an average rating of “Hold” and an average price target of $104.24.

Inspire Medical Systems Stock Up 0.7%

Inspire Medical Systems stock opened at $59.88 on Thursday. The firm has a market cap of $1.71 billion, a P/E ratio of 12.02, a P/E/G ratio of 2.94 and a beta of 0.74. The business has a fifty day moving average of $75.21 and a two-hundred day moving average of $86.49. Inspire Medical Systems, Inc. has a twelve month low of $53.11 and a twelve month high of $176.45.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Wednesday, February 11th. The company reported $1.65 EPS for the quarter, topping the consensus estimate of $0.69 by $0.96. The firm had revenue of $269.08 million during the quarter, compared to analyst estimates of $264.02 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.15 EPS. Equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.